A clinical trial of an experimental cell therapy shows promising results for glioblastoma patients, with tumors disappearing ...

NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

The tumor, which occurs when supportive cells in the brain grow and divide uncontrollably, is extremely aggressive and deadly. Most patients survive only 14 to 16 months after diagnosis.

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

According to the American Brain Tumor Association, glioblastomas represent about 14% of all primary brain tumours, with ...

Man with deadly glioblastoma shows no signs of disease after taking experimental immunotherapy drug ipilimumab, inspiring a ...

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this ...

Glioblastoma is an aggressive brain cancer can affect anyone, at any age, and comes with a poor prognosis. Couple shares symptoms that led to his diagnosis at 38.

Dean Dunphy, 33, was diagnosed with stage 4 brain cancer after experiencing stroke-like symptoms and muscle twitching ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...